Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Approved FDF
Sponsor : Chardan Healthcare
Deal Size : $1.3 million
Deal Type : Public Offering
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering
Details : The Company intends to use the net proceeds for the commercialization activities for Mydcombi, the first and only FDA-approved fixed dose combination ophthalmic spray for pupil dilation.
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
November 25, 2024
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Sponsor : Chardan Healthcare
Deal Size : $1.3 million
Deal Type : Public Offering
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Provides Update On Phase 3 CHAPERONE Study
Details : A drug-device combination of low-dose atropine in the Company’s Optejet dispensing platform is being investigated as a potential treatment for pediatric progressive myopia.
Product Name : MicroPine
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2024
Lead Product(s) : Atropine
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Alliance Global Partners
Deal Size : Undisclosed
Deal Type : Public Offering
Eyenovia, Inc. Announces Pricing of $4 Million Registered Direct Offering
Details : The Company intends to use the net proceeds to fund commercialization activities for Mydcombi and clobetasol propionate, complete the CHAPERONE pediatric myopia clinical study.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
September 27, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Alliance Global Partners
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Launches Clobetasol Propionate Suspension for Post-Ocular Surgery Pain
Details : APP13007 (clobetasol propionate) ophthalmic suspension 0.05% is approved by the FDA for the treatment of post-operative inflammation and pain following ocular surgery.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Inapplicable
September 26, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Dawson James Securities
Deal Size : $5.1 million
Deal Type : Public Offering
Eyenovia Announces Closing of Public Offering
Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
August 23, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Dawson James Securities
Deal Size : $5.1 million
Deal Type : Public Offering
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Dawson James Securities
Deal Size : $5.1 million
Deal Type : Public Offering
Eyenovia Announces Pricing of $5.14 Million Public Offering
Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
August 21, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Dawson James Securities
Deal Size : $5.1 million
Deal Type : Public Offering
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Dawson James Securities
Deal Size : Undisclosed
Deal Type : Public Offering
Eyenovia, Inc. Announces Proposed Public Offering
Details : The Company will fund commercialization activities for Mydcombi (tropicamide and phenylephrine hydrochloride ophthalmic spray) and clobetasol propionate, complete the pediatric myopia clinical study.
Product Name : APP13007
Product Type : Steroid
Upfront Cash : Undisclosed
August 20, 2024
Lead Product(s) : Clobetasol Propionate
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Dawson James Securities
Deal Size : Undisclosed
Deal Type : Public Offering
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Study Phase : Undisclosed
Sponsor : SGN Nanopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Eyenovia and SGN Nanopharma Announce Collaboration for Chronic Dry Eye Disease Treatment
Details : The companies will work to develop SGN’s MNP platform-based Cyclosporine formulation for use with Eyenovia’s Optejet dispenser for treatment of chronic dry eye disease.
Product Name : Undisclosed
Product Type : Peptide
Upfront Cash : Undisclosed
July 30, 2024
Lead Product(s) : Cyclosporine
Therapeutic Area : Ophthalmology
Highest Development Status : Undisclosed
Sponsor : SGN Nanopharma
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Collaboration
Eyenovia and Senju Pharmaceutical Sign Collaboration for Chronic Dry Eye Treatment
Details : both companies intend to work to develop Senju’s corneal epithelial candidate, SJP-0035, for use with Eyenovia’s Optejet dispensing technology, as a potential treatment for chronic dry eye disease.
Product Name : SJP-0035
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
July 23, 2024
Lead Product(s) : Fonadelpar
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : SENJU PHARMACEUTICAL CO LTD
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Eyenovia Provides Update on Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Details : Mydcombi is FDA approved, first-in-class fixed-dose-combination product (tropicamide 1% and phenylephrine 2.5% ophthalmic spray) for pharmacologic mydriasis (eye dilation).
Product Name : Mydcombi
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : Phenylephrine Hydrochloride,Tropicamide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable